We stand at a pivotal moment for cancer research - and in today's challenging funding environment, the role of foundations and strategic partnerships is more critical than ever in sustaining and accelerating vital scientific discovery. Yet, in this moment of uncertainty, our mission remains clear: accelerating the translation of innovative cancer research into life-saving treatments. We continue to fill critical funding gaps and foster partnerships that span academia, industry, and clinical practice. We fund science with the biggest potential for impact, even if results aren’t guaranteed. And we take chances on collaborative projects that draw on novel, multidisciplinary approaches.

In 2024, we proudly surpassed a significant milestone: over $260 million in total grants awarded since our inception just seven years ago. The projects we support span a broad spectrum of cancer types and research stages, and are located across more than 110 institutions in 16 countries. This year, we also brought together leading researchers to tackle critical challenges like discovering new treatments for intractable brain cancers and targeting the tumor microenvironment, because we believe that breaking down institutional and disciplinary boundaries is critical to driving progress.

Within these pages, you'll discover stories and data that illustrate the incredible impact of our dedicated scientific community. This Annual Report is a testament to their remarkable achievements over the past year, and to our ongoing shared commitment to the fight against cancer.

As I reflect on the past year, I'm struck by the incredible momentum building within The Mark Foundation for Cancer Research. It's truly inspiring to see our vision evolve and expand in ways we could only have hoped for.

In 2024, we awarded more than $34 million in grant funding, supporting a wide range of projects led by world-leading cancer researchers at every career stage. Our commitment to collaboration has deepened, with exciting new partnerships forged with other organizations that will amplify our collective impact. Perhaps most rewarding is witnessing more and more Mark Foundation-funded research progress toward patient impact with key publications and new clinical trials. These tangible steps forward underscore the vital role our community plays in transforming cancer care.

I am immensely proud of the dedication shown by our entire team, led by Ryan and Ray, our brilliant grantees, and the invaluable contributions of our scientific and industry advisors, grant reviewers, and partners. Their unwavering commitment makes all of this possible.

Thank you for being a part of this essential mission. Together, we are working toward a future free from the burden of cancer.